You are here

  • Home
  • Archive
  • Volume 22, Issue 2
  • SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

Article metrics

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

 

Online download statistics by month:

Online download statistics by month: February 2017 to March 2024

AbstractFullPdf
Feb 20174133537
Mar 20171934423
Apr 20171462213
May 20171152514
Jun 201765125
Jul 201711653
Aug 20177841
Sep 2017163163
Oct 20176763
Nov 20179462
Dec 20179354
Jan 20188452
Feb 20187842
Mar 201895102
Apr 20186462
May 20187111
Jun 20186941
Jul 20186175
Aug 201812473
Sep 20188230
Oct 201810745
Nov 201814952
Dec 201813340
Jan 20199461
Feb 201913863
Mar 20198053
Apr 20196220
May 20197452
Jun 20197220
Jul 20196483
Aug 20192920
Sep 20196550
Oct 20193600
Nov 20195652
Dec 20195710
Jan 20201811
Feb 20202910
Mar 20203011
Apr 20202942
May 20203410
Jun 20201910
Jul 20205223
Aug 20201310
Sep 20203500
Oct 20204641
Nov 20202000
Dec 20202900
Jan 20212733
Feb 20213812
Mar 20212910
Apr 20212000
May 20212400
Jun 2021110
Jul 2021310
Aug 2021310
Sep 2021553
Oct 20211421
Nov 20215500
Dec 20212822
Jan 20228931
Feb 20221800
Mar 20223621
Apr 20222822
May 20224830
Jun 20224600
Jul 20222500
Aug 20228321
Sep 20223610
Oct 20224110
Nov 20223010
Dec 20222420
Jan 20232810
Feb 20234711
Mar 20231200
Apr 2023600
May 20231700
Jun 20231010
Jul 20232000
Aug 20231000
Sep 20231001
Oct 20231510
Nov 20232000
Dec 20233421
Jan 20241100
Feb 20241801
Mar 20242811
Total4878344176